Literature DB >> 11676825

Inhibition of ATP-binding cassette transporter downregulates interleukin-1beta-mediated autocrine activation of human dermal fibroblasts.

D Lottaz1, Z Beleznay, M Bickel.   

Abstract

Fibroblasts constitute an important source of cytokines during inflammatory processes in the skin. Interleukin-1 is a potent, pleiotropic cytokine that is induced in activated human dermal fibroblasts. Interleukin-1 further induces many inflammatory mediators, including the chemokine interleukin-8. As fibroblasts express both interleukin-1 and the interleukin-1 receptor complex, the cellular response may be enhanced by autocrine activation. Interleukin-1alpha and interleukin-1beta lack a signal peptide and are translocated at the plasma membrane using an alternative secretory pathway, which may involve ATP-binding cassette transporter proteins. We hypothesize that inhibition of this pathway prevents secretion of interleukin-1, thereby downregulating interleukin-1-dependent autocrine induction of interleukin-8. We used the ATP-binding cassette 1 transporter inhibitor glybenclamide, which has been previously shown to block interleukin-1beta secretion in human monocytes. Using enzyme-linked immunosorbent assay, we assessed the effect of glybenclamide on interleukin-8 production in human dermal fibroblasts. In interleukin-1beta-transfected human dermal fibroblasts, interleukin-8 was induced through an autocrine activity of interleukin-1beta. Glybenclamide disabled this activation loop and significantly reduced interleukin-8. In human dermal fibroblasts that were stimulated with tumor necrosis factor alpha to reach high interleukin-1 expression levels, glybenclamide similarly suppressed interleukin-8. In contrast, glybenclamide did not affect interleukin-8 production in cells stimulated with interleukin-1 only. Glybenclamide did not affect caspase-1 in fibroblasts, which was expressed as an inactive precursor form, irrespective of treatments with tumor necrosis factor alpha and/or glybenclamide. Using overexpressing, interleukin-1-transfected COS-1 cells, inhibition of interleukin-1alpha and interleukin-1beta secretion was directly demonstrated on Western blots. These results are consistent with glybenclamide preventing externalization of interleukin-1 and subsequent autocrine induction of interleukin-8 in human dermal fibroblasts. Acting through such a mechanism, ATP-binding cassette transporter inhibitors may downregulate inflammation locally.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676825     DOI: 10.1046/j.0022-202x.2001.01451.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

Review 1.  Inflammasome Activation in Chronic Glomerular Diseases.

Authors:  Sabena M Conley; Justine M Abais; Krishna M Boini; Pin-Lan Li
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

2.  Secretome analysis reveals an Arabidopsis lipase involved in defense against Alternaria brassicicola.

Authors:  Il Seok Oh; Ae Ran Park; Min Seok Bae; Sun Jae Kwon; Young Soon Kim; Ji Eun Lee; Na Young Kang; Sumin Lee; Hyeonsook Cheong; Ohkmae K Park
Journal:  Plant Cell       Date:  2005-08-26       Impact factor: 11.277

3.  Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network.

Authors:  Arturo V Orjalo; Dipa Bhaumik; Bridget K Gengler; Gary K Scott; Judith Campisi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-28       Impact factor: 11.205

Review 4.  NLRP3 Activation and Its Relationship to Endothelial Dysfunction and Oxidative Stress: Implications for Preeclampsia and Pharmacological Interventions.

Authors:  Priscila Rezeck Nunes; Sarah Viana Mattioli; Valeria Cristina Sandrim
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

Review 5.  Pharmacological Inhibitors of the NLRP3 Inflammasome.

Authors:  Ayesha Zahid; Bofeng Li; Arnaud John Kombe Kombe; Tengchuan Jin; Jinhui Tao
Journal:  Front Immunol       Date:  2019-10-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.